As a leading cause of respiratory disease, influenza A virus (IAV) presents a pandemic threat in annual seasonal outbreaks. Given the limitation of existing anti-influenza therapies, there remains to be a requirement for new drugs. Compound Yi-Zhi-Hao pellet (CYZH) is a famous traditional Chinese medicine (TCM) used in the clinic, whose formula has been recorded in Complication of National Standard for Traditional Chinese Medicine to treat common cold. In this study, we found that CYZH exhibited a broad-spectrum anti-influenza activity and inhibited the expression of viral RNA and proteins in vitro. Mechanistically, CYZH had no inhibitory activities against viral protein hemagglutinin and IAV RNA-dependent RNA polymerase. Instead, it induced activation of erythroid 2-related factor 2 (Nrf2) and nuclear factor kappa B (NF-kappa B), which subsequently upregulated heme oxygenase-1 (H0-1) expression. Also, CYZH protected cells from oxidative damage induced by reactive oxygen series. In conclusions, CYZH inhibits IAV replication in vitro, at least partly by activating expression of the Nrf2/H0-1 pathway. (C) 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND.
[1]Chinese Acad Med Sci, Inst Med Biotechnol, Beijing 100050, Peoples R China.
[2]Peking Union Med Coll, Beijing 100050, Peoples R China.
[3]Shanghai Univ Med & Hlth Sci, Sch Med Technol, Shanghai 201318, Peoples R China.
[4]Xinjiang Med Univ, Affiliated Hosp 6, Dept Pharm, Urumqi 830002, Peoples R China.
(8.0+极速模式)